Go Pro
OTCMKTS:HEMA

HemaCare (HEMA) Stock Price, News & Analysis

HemaCare logo
$25.31 +0.15 (+0.60%)
As of 01/3/2020

About HemaCare Stock (OTCMKTS:HEMA)

Key Stats

Today's Range
$25.31
▼
$25.31
50-Day Range
$25.31
▼
$25.31
52-Week Range
$8.62
▼
$26.23
Volume
5,400 shs
Average Volume
39,950 shs
Market Capitalization
$346.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

HemaCare Corporation was a biotechnology company that supplied human-derived biological materials for research and drug development. Its offerings included blood components, primary human cells, and other biospecimens used in studies involving immunology, cell therapy, gene therapy, regenerative medicine, and related life sciences applications.

The company worked with pharmaceutical, biotechnology, academic, and medical research organizations, providing donor-derived materials and collection services designed to support preclinical research and the development of advanced therapies. HemaCare was based in California and served customers in the United States and internationally.

HemaCare operated as an independent public company under the OTCMKTS symbol HEMA before being acquired by Charles River Laboratories in 2019. Following the transaction, its operations became part of Charles River’s broader portfolio of research products and services.

AI Generated. May Contain Errors.

Receive HEMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HemaCare and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HEMA Stock News Headlines

First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
HEMA Historical Data
See More Headlines

HEMA Stock Analysis - Frequently Asked Questions

HemaCare's stock was trading at $25.31 at the beginning of the year. Since then, HEMA stock has increased by 0.0% and is now trading at $25.31.

Shares of HEMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that HemaCare investors own include First Majestic Silver (AG), Cognizant Technology Solutions (CTSH), Canadian Solar (CSIQ), Conduent (CNDT),

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Miscellaneous Health & Allied Services
Sub-Industry
N/A
Current Symbol
OTCMKTS:HEMA
CIK
801748
Fax
N/A
Employees
N/A
Year Founded
1978

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
13,691,000
Free Float
N/A
Market Cap
$346.52 million
Optionable
Not Optionable
Beta
1.47

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (OTCMKTS:HEMA) was last updated on 9/28/2026 by MarketBeat.com Staff.
From Our Partners